Cyplasin Biomedical Ltd. Announces Results of Second Animal Efficacy Study



    CYPL: OTCBB, Frankfurt Exchange WKN:XYIA

    EDMONTON, Sept. 29 /CNW/ - Cyplasin Biomedical Ltd (CBL) announces the
results from the second animal efficacy study of its lead product
Cyplasin-SC(TM). The second study of Cyplasin-SC(TM) was intended to be
performed as before where mice with a suppressed immune system were given
human melanoma cells in order to create melanoma tumors in the mice. These
melanoma tumors were allowed to grow to a sufficient size to allow for
repeated microinjection of Cyplasin-SC at or near the tumor site. After a
specified period of time the tumors were analyzed to determine if the
Cyplasin-SC has retarded or stopped the growth of the tumor.
    "Our first study confirmed a definitive correlation with the amount of
Cyplasin-SC(TM) being given versus a reduced tumor size. The second study did
not give the same clear positive results as the previous efficacy study as
data showed variable results with respect to the tumor size reduction" stated
Professor Petzelt CSO of the Company. He further stated "We have taken time to
understand these results and believe they may be related to certain variables
introduced unintentionally into the execution of the study which we need to
better control before further experiments using a purified Cyplasin can be
initiated."
    Cyplasin-SC(TM) is being developed for use as an anticancer therapeutic
drug for melanoma and skin cancer.

    About Melanoma

    Around 160,000 new cases of new melanoma cases are diagnosed worldwide
each year. Melanoma is more frequently found in Caucasian males and is more
common in Caucasian populations living in sunny climates than in other groups.
Market statistics for skin cancer and melanoma show that melanoma currently
affects more than 2.4 million people worldwide with 62,000 new cases being
reported in the USA every year. Australia has the highest rate of melanoma in
the world among males and has the second highest rate in the world among
females (Australia's Health 2004, AIHW). According to the WHO Report the world
wide incidence has doubled over the past 20 years with about 48,000 melanoma
related deaths occurring worldwide per annum.

    Forward-Looking Statements

    This Press release includes and is based, inter alia, on forward-looking
information and statements that are subject to risks and uncertainties that
could cause actual results to differ. Such forward-looking information and
statements are based without limitation, as statements regarding future drug
development activities, anticipated products, or anticipated future revenues,
benefits or advantages, and the future plans and objectives of the Company,
that involve inherent risks and uncertainties and are subject to factors, many
of which are beyond the Company's control, such as market acceptance of new
products and services, changes in governmental regulations, interest rates,
fluctuations in currency exchange rates and such other factors as may be
discussed from time to time that may cause actual results or performance to
differ materially from those currently anticipated in such statements. These
expectations, estimates and projections are generally identifiable by
statements containing words such as "expects", "believes", "estimates" or
similar expressions. Although Cyplasin Biomedical Ltd., believes that its
expectations and the information in this Press release were based upon
reasonable assumptions at the time when they were made, it can give no
assurance that those expectations will be achieved or that the actual results
will be as set out in this Press release. Cyplasin Biomedical Ltd., makes no
representation or warranty, expressed or implied, as to the accuracy,
reliability or completeness of the information in the Press release, and
neither Cyplasin Biomedical nor any of their directors, officers or employees
will have any liability to you or any other persons resulting from your use of
the information in the Press release. The OTCBB Exchange has not reviewed and
does not accept responsibility for the adequacy or accuracy of this news
release.





For further information:

For further information: Garth Likes, President & CEO, Cyplasin
Biomedical Ltd., www.cyplasin.com, Tel 001-780-469-2975, Fax 001-780-699-7933,
glikes@cyplasin.com; Professor Christian Petzelt (CSO), Cyplasin Biomedical
Ltd., www.cyplasin.com, Tel 0049-30-95992761, cpetzelt@cyplasin.com

Organization Profile

CYPLASIN BIOMEDICAL LTD.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890